Enzyme Replacement Therapy Market Opportunity Analysis, 2018-2026

REPORT DESCRIPTION
Enzyme Replacement Therapy Market – Overview
Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of
enzymes that causes a specific disease condition called lysosomal storage disease. Enzyme replacement therapy is
used in Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter
syndrome, and Pompe disease. Enzymes are obtained from sources such as human cells, animal cells, and
recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents
permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or
monthly doses depending upon the disease. For instance, in order to address enzyme deficiency in Gaucher
disease, modified version of glucocerebrosidase is administered intravenously every two weeks. Enzyme
replacement is associated with fewer side effects than other treatment methods. However, enzyme replacement
therapy may be inconvenient for some patients such as children and geriatric population due to intravenous
administration. It may result in local infusion reaction or hypersensitive reactions in the form of local rash, fever,
edema, bronchospasm or hypotension.
Click To Continue Reading on Enzyme Replacement Therapy Market
© Coherent market Insights. All Rights Reserved